ADC Therapeutics (ADCT) Common Equity (2020 - 2026)
ADC Therapeutics (ADCT) posted Common Equity of -$216.4 million for Q1 2026, down 16.44% sequentially from -$185.8 million in Q4 2025, and up 9.17% YoY from -$198.2 million in Q1 2025.
ADC Therapeutics (ADCT) Common Equity (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Common Equity for 7 years, with the latest figure at -$216.4 million in Q1 2026.
- Quarterly Common Equity rose 9.17% year-over-year to -$216.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$216.4 million (up 9.17% YoY) and the FY2025 annual result came in at -$185.8 million, up 8.29% from the prior year.
- Common Equity eased to -$216.4 million in Q1 2026 per ADCT's latest filing, from -$185.8 million in the prior quarter.
- Over five years, Common Equity peaked at $162.7 million in Q1 2022 and troughed at -$238.2 million in Q1 2025.
- A 5-year average of -$101.6 million and a median of -$160.1 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2026: Common Equity sank 784.15% in 2024, then rose 9.17% in 2026.
- Over 5 years, Common Equity stood at $79.5 million in 2022, then sank by 286.59% to -$148.2 million in 2023, then plunged by 36.69% to -$202.6 million in 2024, then rose by 8.29% to -$185.8 million in 2025, then slipped by 16.44% to -$216.4 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$216.4 million, -$185.8 million, and -$238.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 9.79 Bn |
| 10 | ADC Therapeutics | 151.73 Mn | -67.38 Mn | 17.14 Mn | -228.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -228.21 Mn |
| Mar 31, 2026 | -216.38 Mn |
| Dec 31, 2025 | -185.83 Mn |
| Sep 30, 2025 | -238.18 Mn |
| Jun 30, 2025 | -199.18 Mn |
| Mar 31, 2025 | -238.22 Mn |
| Dec 31, 2024 | -202.64 Mn |
| Sep 30, 2024 | -171.95 Mn |
| Jun 30, 2024 | -131.67 Mn |
| Mar 31, 2024 | -194.45 Mn |
| Dec 31, 2023 | -148.25 Mn |
| Sep 30, 2023 | -64.25 Mn |
| Jun 30, 2023 | -19.70 Mn |
| Mar 31, 2023 | 28.42 Mn |
| Dec 31, 2022 | 79.45 Mn |
| Jun 30, 2022 | 115.35 Mn |
| Mar 31, 2022 | 162.67 Mn |
| Dec 31, 2021 | 154.03 Mn |
| Jun 30, 2021 | 243.92 Mn |
| Mar 31, 2021 | 297.97 Mn |